Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Retained Earnings (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed Retained Earnings for 5 consecutive years, with -$570.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 72343.35% to -$570.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$570.0 million, a 72343.35% decrease, with the full-year FY2024 number at $255000.0, up 750.0% from a year prior.
  • Retained Earnings was -$570.0 million for Q3 2025 at Caribou Biosciences, down from -$542.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $789000.0 in Q3 2024 to a low of -$570.0 million in Q3 2025.
  • A 5-year average of -$137.0 million and a median of -$1.5 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: skyrocketed 750.0% in 2024, then plummeted 72343.35% in 2025.
  • Caribou Biosciences' Retained Earnings stood at -$135000.0 in 2021, then tumbled by 1024.44% to -$1.5 million in 2022, then surged by 101.98% to $30000.0 in 2023, then surged by 750.0% to $255000.0 in 2024, then plummeted by 223629.41% to -$570.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Retained Earnings are -$570.0 million (Q3 2025), -$542.5 million (Q2 2025), and -$488.4 million (Q1 2025).